Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.
written on 08.04.2014
Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.
See our Cookie Privacy Policy Here